Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 20/20 | 0.63 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.59 |
| ▸ | PDE5A | O76074 | 2/20 | 0.58 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.58 |
| ▸ | PDE2A | O00408 | 1/20 | 0.58 |
| ▸ | PDE8A | O60658 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.58 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16981652 | 0.99 | PDE9A (0.65) | PDE9APDE1CPDE5APDE1BPDE2A | |
| SCHEMBL22042950 | 0.94 | PDE9A (0.55) | PDE9APDE1CPDE5APDE1BPDE2A | |
| SCHEMBL22042861 | 0.88 | PDE9A (0.50) | PDE9APDE1CPDE5APDE1BPDE2A | |
| SCHEMBL17603784 | 0.88 | PDE9A (0.61) | PDE9APDE1C | |
| SCHEMBL22042919 | 0.85 | PDE9A (0.62) | PDE9APDE5APDE1BPDE2APDE8A | |
| SCHEMBL23562705 | 0.83 | PDE9A (0.52) | PDE9APDE1CPDE5APDE1BPDE2A | |
| SCHEMBL17604293 | 0.82 | PDE9A (0.73) | PDE9APDE1C | |
| SCHEMBL6897438 | 0.81 | PDE9A (0.60) | PDE9APDE1C | |
| SCHEMBL14997318 | 0.80 | PDE9A (0.76) | PDE9APDE1C | |
| SCHEMBL3099231 | 0.79 | PDE9A (0.74) | PDE9APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617269-B2 | N-substituted pyrazolo [3,4-D] pyrimidine ketone compound, and preparation process and use thereof | SUN YAT-SEN UNIVERSITY (CN) | 2017-04-11 | — | — | US | disclosed |
| US-9617269-B2 | N-substituted pyrazolo [3,4-D] pyrimidine ketone compound, and preparation process and use thereof | SUN YAT-SEN UNIVERSITY (CN) | 2017-04-11 | — | — | US | disclosed |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20150218168-A1 | N-SUBSTITUTED PYRAZOLO [3,4-D] PYRIMIDINE KETONE COMPOUND, AND PREPARATION PROCESS AND USE THEREOF | SUN YAT-SEN UNIVERSITY (CN) | 2015-08-06 | — | — | US | disclosed |
| US-20150218168-A1 | N-SUBSTITUTED PYRAZOLO [3,4-D] PYRIMIDINE KETONE COMPOUND, AND PREPARATION PROCESS AND USE THEREOF | SUN YAT-SEN UNIVERSITY (CN) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | PDE3A, PDE2A, PDE5A | PDE9A 11/4885PDE1C 18/4885PDE5A 3/4885 |
| US-20150218168-A1 | N-SUBSTITUTED PYRAZOLO [3,4-D] PYRIMIDINE KETONE COMPOUND, AND PREPARATION PROCESS AND USE THEREOF | PDE3B, PDE3A, PDE2A | PDE9A 4/4885PDE1C 187/4885PDE5A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.